BMJ Open

Effects of adjunctive brexpiprazole on sleep-wake and circadian parameters in youth with depressive disorders: study protocol for a clinical trial

Joanne S Carpenter 1,2, Natalia Zmicerevska 1,2, Jacob J Crouse 1,2, Alissa Nichles 1,2, Alexandra Garland,1 Yun Ju Christine Song,1 Chloe Wilson 1,2, Cathrin Rohleder 1,2, Catherine McHugh 1,2, F. Markus Leweke 1,2, Dagmar Koethe,1 Elizabeth M Scott,1,2 Ian B Hickie1

ABSTRACT

Introduction Sleep-wake and circadian disturbance is a key feature of mood disorders with a potential causal role and particular relevance to young people. Brexpiprazole is a second-generation antipsychotic medication with demonstrated efficacy as an adjunct to antidepressant treatment for major depressive disorder (MDD) in adults, with preliminary evidence suggesting greater effectiveness in subgroups of depressed patients with sleep disturbances. This clinical trial aims to evaluate the relationships between changes in sleep-wake and circadian parameters and changes in depressive symptoms following adjunctive brexpiprazole treatment in young adults with MDD and sleep-wake disturbance.

Methods and analysis This study is designed as a 16 week (8 weeks active treatment, 8 weeks follow-up) mechanistic, open-label, single-arm, phase IV clinical trial and aims to recruit 50 young people aged 18–30 with MDD and sleep-wake cycle disturbance through an early intervention youth mental health clinic in Sydney, Australia. At baseline, participants will undergo multidimensional outcome assessment and subsequently receive 8 weeks of open-label treatment with brexpiprazole as adjunctive to their stable psychotropic medication. Following 4 weeks of treatment, clinical and self-report measures will be repeated. Ambulatory sleep-wake monitoring will be conducted continuously for the duration of treatment. After 8 weeks of treatment, all multidimensional outcome assessments will be repeated. Follow-up visits will be conducted 4 and 8 weeks after trial completion (including sleep-wake, clinical and self-report assessments).

Circadian rhythm biomarkers including salivary melatonin, cortisol and core body temperature will be collected during an in-lab assessment. Additionally, metabolic, inflammatory and genetic risk markers will be collected at baseline and after 8 weeks of treatment.

Ethics and dissemination This trial protocol has been approved by the Human Research Ethics Committee of the Sydney Local Health District (X19-0417 and 2019/ETH2986, Protocol Version 1–3, dated 25 February 2021). The results of this study, in deidentified form, will be disseminated through publication in peer-reviewed journals, scholarly book chapters, presentation at conferences and publication in conference proceedings.

Trial registration number ACTRN12619001456145.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ Use of a comprehensive battery that includes ecologically valid and laboratory-based circadian assessments (alongside genetic, metabolic and inflammatory markers) may provide greater insights into the antidepressant mechanisms of adjunctive brexpiprazole.

⇒ Participants will receive a psychoeducational session about sleep and circadian rhythms, including information on how to improve their sleep-wake cycle based on their individual actigraphy data.

⇒ This trial focuses on ascertainment of the current 24-hour sleep-wake cycle and will not examine possible factors that may contribute to sleep/circadian disruption in the long term (eg, stressors) or the physiologic properties of sleep.

⇒ Some extraneous factors that influence the sleep-wake cycle and/or circadian rhythms (eg, ambient temperature, natural light exposure) are not measured in this study.

INTRODUCTION

In young adults, major depressive disorder (MDD) is highly prevalent, recurrent and comorbid with other mental and physical conditions, generating a substantial burden of disease and disability.1,2 While multiple psychological and pharmacological treatments are commonly provided, a large proportion of patients fail to respond to first-line psychotherapy or antidepressant treatments,3-10 and augmentation with a second-generation antipsychotic is often recommended in these treatment-resistant cases.11 12 Sleep-wake cycle disturbances are common features of depressive disorders,
including insomnia, hypersomnia, abnormal sleep duration and abnormal timing of 24-hour patterns of rest/activity. Moreover, abnormalities in biological circadian rhythms (eg, melatonin) have been reported, suggesting that in some cases sleep disturbances are accompanied or underpinned by disturbances of the underlying circadian system.

The human circadian system is controlled by a master oscillator in the brain’s hypothalamus (suprachiasmatic nucleus) which projects to circuits that govern biobehavioural processes often altered in depression (eg, mood, vigilance and 24-hour sleep-wake cycle). The circadian system is primarily entrained by bright light, and its functioning can be disrupted by factors including aberrant light exposure and irregular sleep-wake behaviours. Adolescents and young adults are particularly vulnerable to circadian perturbations due to significant developmental changes in circadian rhythms across this age period, and sleep-wake phase delays are common in young people with depressive disorders. Recently, we reported delayed and disrupted circadian rhythms in a subgroup of young people with depressive disorders (who also presented with greater symptom severity). During adolescence there is a phase shift in the circadian rhythm of the sleep-wake cycle, such that adolescents typically develop a biobehavioural preference for going to sleep later and waking later (a manifestation of changes in the biology of the circadian system). Furthermore, there is some evidence that correction of circadian abnormalities is associated with antidepressant effects of treatments targeting the circadian system such as agomelatine and light therapy.

Brexpiprazole is a second-generation antipsychotic with demonstrated efficacy by multiple randomised controlled trials as an adjunct to antidepressant treatment in MDD in adults, however, the mechanism of antidepressant action is unknown. The pharmacodynamic properties of brexpiprazole, together with evidence from preclinical studies, suggest that there may be specific effects on anxiety, cognition and sleep. Further, there is preliminary evidence to suggest that brexpiprazole may have greater effectiveness in subgroups of depressed patients with sleep disturbances, anxiety or irritability. As an adjunctive treatment in patients with MDD with inadequate response to antidepressant treatment, brexpiprazole has been reported to lead to clinical improvement of sleep disturbances (eg, insomnia) and depressive symptoms, as well as improvement of daytime alertness and functioning. This pattern of changes is consistent with effects on circadian rhythms, with potential influences on the entire 24-hour pattern of rest/activity, rather than simply on sleep period (in isolation). To improve the personalisation of treatment selection for mood disorders, a greater understanding of the mechanisms of antidepressant action of specific compounds is needed.

The goal of this clinical trial is to investigate whether the effect of brexpiprazole on depressive symptoms is associated with changes in 24-hour sleep-wake or circadian parameters in young people with MDD. While disturbances in electrophysiological measures of sleep (eg, REM sleep) have been considered to represent biomarkers for depression, this trial focuses instead on the investigation and measurement of biobehavioural changes associated with the circadian system (eg, rest/activity, melatonin, cortisol and core body temperature rhythms), rather than changes in electrophysiological sleep architecture (beyond the scope of this study).

**METHODS AND ANALYSIS**

**Study objectives**

The primary objective of this study is to determine if changes in depressive symptoms following adjunctive brexpiprazole treatment are correlated with changes in sleep-wake or circadian parameters in youth with depressive disorders. The secondary objective is to determine if changes in social and occupational functioning following adjunctive brexpiprazole are correlated with changes in sleep-wake or circadian parameters in youth with depressive disorders. The tertiary objectives of this study are to determine if changes in depressive symptoms or changes in sleep-wake or circadian parameters following adjunctive brexpiprazole treatment are associated with a range of multidimensional outcome measures in youth with depressive disorders (eg, other mental illness symptoms, self-harm and suicidal thoughts and behaviours, physical health, alcohol/substance use and genetic markers).

**Trial design**

This investigator-initiated, mechanistic study involving 50 young people with depressive disorders and sleep-wake cycle disturbances is designed as a 16-week (8 weeks active treatment, 8 weeks follow-up) open-label, single-arm, phase IV clinical trial.

**Participants**

Participants aged 18–30 years with a diagnosis of MDD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), criteria on the current major depressive episode of moderate severity. The inclusion criteria for this trial are as follows: (1) aged 18–30, (2) diagnosis of MDD as per DSM-5 (Structured Clinical Interview for DSM; SCID) criteria, (3) current major depressive episode of moderate severity...
as defined by a Quick Inventory of Depressive Symptomatology rating ≥11 at two assessments 2 weeks apart, (4) failure to respond to at least one adequate (minimum 4 weeks) trial of pharmacological treatment, (5) current antidepressant treatment with an SSRI or SNRI (including citalopram, fluoxetine, paroxetine, sertraline, escitalopram, venlafaxine, desvenlafaxine or duloxetine) for at least 6 weeks, at a stable dose for 2 weeks prior to study commencement and (6) a perturbed sleep-wake cycle as evidenced by: delayed sleep onset; delayed sleep offset; disrupted sleep; high day-to-day variability of sleep-wake cycle; non-restorative sleep or daytime fatigue.

Exclusion criteria are as follows: (1) any adjunctive antipsychotic treatment for the current episode in the past month, (2) use of medications which affect sleep, melatonin, circadian rhythms or alertness (eg, agomelatine, modafinil), (3) primary psychotic disorder, (4) acute suicidal behaviour (score of 6 on Comprehensive Assessment of At-Risk Mental States (CAARMS) item 7.3,48 (5) evidence of a medical condition (primary, respiratory, neurological) that could contribute to sleep-wake dysfunction, (6) significant alcohol or substance misuse or dependence (assessed via DSM-5 SCID and WHO Alcohol, Smoking and Substance Involvement Screening Test),49 50 (7) shift work or (8) recent transmeridian travel (ie, participants will be required to wait 3 days for each jet lag hour before entering the study), (9) previous hypersensitivity to brexpiprazole, (10) taking CYP2D6 or CYP3A4 inhibitors (or other contraindicated medications listed in the Rexulti product information) and (11) pregnancy or lactation.

Study course and procedure

Patients presenting for mental healthcare who may be eligible for the study will be screened by phone before being invited to participate and attend an enrolment visit. The enrolment visit will formally assess eligibility criteria and confirm the presence of MDD as per DSM-5 (SCID).46 Participants will be provided with an actigraphy device (non-invasive wrist-worn device used to objectively measure rest/activity patterns) and will be given instructions to wear the device for the following 2 week period.

Visit 1 (Baseline): Within 2 weeks of completing the diagnostic and screening assessments, data from the actigraphy device will be downloaded and reviewed. A further assessment of depressive symptom severity (QIDS Clinician-Rated; QIDS-CR)47 will be conducted to ensure participants meet all inclusion criteria. Bloods will be collected for assessment of metabolic and inflammatory measures and genomic analysis. Clinical and self-report assessments will be conducted, as well as circadian assessments in which participants will remain in the sleep lab overnight. The following morning, participants will attend a 1-hour psychoeducation session about sleep and circadian rhythms covering the following topics: (1) sleep and circadian education with tailored discussion based on their personal actigraphy data; (2) individualised plan for progressive sleep rescheduling; and (3) lifestyle factors and behaviours impacting on sleep (eg, exercise, light, sleep environment, sleep regulation, foods, stress, anxiety and mood).

Once all baseline clinical and self-report assessments have been conducted, and the medical assessment completed by the study doctor to confirm inclusion and exclusion criteria, participants will be issued with the study medication to receive 8 weeks of open-label pharmacotherapy with brexpiprazole (REXULTI-Lundbeck) as adjunctive to their stable psychotropic medication (treatment as usual). Brexpiprazole will be provided to participants at visit 1 (baseline) and visit 2 (week 4) for the following 4 weeks and will be titrated from 1 mg once daily in week 1, to 2 mg once daily in weeks 2–8.

Patients will receive 2 mg/day, once daily as tablets, for oral use. The brexpiprazole dosage will be steadily increased from 1 mg/day during week 1, to 2 mg/day during weeks 2–8 (up-titration). This is the dosage and titration regimen recommended for adjunctive use in MDD by the Federal Drug Administration (USA). Several previous clinical trials have used this titration regimen from 1 mg to 2 mg,34 40 51 and a dose of 2 mg has been shown to be effective in reducing depressive symptoms.33 As doses higher than 2 mg have been shown to increase incidence of akathisia,37 a maximum dose of 2 mg will be used in the present study to minimise side effects.

Monitoring visits: Participants will be contacted by telephone on a weekly basis for the duration of the 8-week treatment period to monitor adverse events and adherence. Any changes in concomitant medications will also be investigated and recorded. In addition, participants will be provided with a medication diary and asked to complete the study during the study to monitor adherence. More detailed information about potential side effects will be further assessed by the study doctor at visits 2, 3, 4 and 5 using the UKU Side Effect Rating Scale,52 Abnormal Involuntary Movement Scale53 and the Simpson-Angus Scale for evaluation of extrapyramidal symptoms.54

Visit 2 (week 4): Following 4 weeks of the treatment phase, participants will return for clinical and self-report assessments to assess changes in clinical and functional measures.

Visit 3 (week 8): Following 8 weeks of the treatment phase, participants will return to complete clinical and self-report assessments and will also complete a second circadian (overnight) in-lab assessment. Bloods will be collected at this visit for follow-up metabolic and inflammatory markers. Participants will continue to be provided the brexpiprazole for up to 12 months following completion of the treatment phase as clinically indicated, at the discretion of their treating clinician. Analyses will account for whether participants have continued or discontinued the medication during the follow-up period.

Visits 4 and 5 (follow-up visits 1 and 2, 12 and 16 weeks, respectively): 12 and 16 weeks after commencing treatment (ie, 4 and 8 weeks after completing the 8-week treatment period, respectively), participants will return to complete clinical and self-report assessments. Participants
will be provided with an actigraphy device to wear for 2 weeks prior to these assessments. Participants will be reimbursed for their time and the cost of transportation to and from the research sites.

**Outcomes**
Outcome measures are summarised in table 1.

**Primary outcomes**
The primary endpoint will be the correlation between change in sleep-wake and circadian parameters and change in depressive symptoms from baseline to week 8. Sleep items in the primary depressive symptom measures (QIDS-CR total score, QIDS-SR total score, The Montgomery-Åsberg Depression Rating Scale (MADRS) total score) will be removed in analyses to provide a measure of depressive symptoms not biased by changes in sleep-wake parameters.

**Secondary outcomes**
The secondary endpoint will be correlation between change in sleep-wake and circadian parameters and change in functioning from baseline to week 8.

**Tertiary outcomes**
Tertiary endpoints will be correlation between change in sleep-wake and circadian parameters and other multidimensional outcome measures based on assessments of symptoms, self-harm and suicidal thoughts and behaviours, physical health and alcohol/substance use. Further tertiary endpoints will be comparison of primary endpoints between Clinical Stages, illness trajectories and genetic variants with potential relevance to mood disorders and/or circadian rhythms (eg, CLOCK and BMAL1).

**Assessments**
Assessments used here are based on the multidimensional assessment and outcomes framework and include clinical and self-report ratings of mental health symptoms, social and occupational functioning, self-harm, suicidal thoughts and behaviours, physical health, alcohol and substance use, illness type, stage and trajectory, as well as circadian parameters and metabolic, inflammatory and genetic markers. Our recent research indicates the capacity of the multidimensional outcomes framework to further our understanding of the pathophysiological mechanisms and illness progression in this cohort, as well as to inform more personalised and measurement-based models of care.

**Diagnostic assessments**
The presence of MDD and any comorbidity will be evaluated using SCID (30–75 min to complete).

**Mental risk assessment**
Acute suicidal behaviour will be assessed by the relevant subscale of the CAARMS (5 min to complete).

**Clinical assessments**
The clinical interview is expected to take around 35 min to complete.

1. Clinician-rated Quick Inventory of Depressive Symptomatology (QIDS-CR): assesses the nine criterion symptom domains designated by the DSM to diagnose an MDE.
2. MADRS: will also be used to assess depressive symptoms, to allow for direct comparisons with previous studies of brexpiprazole in MDD.
3. Young Mania Rating Scale: an 11-item, multiple-choice diagnostic questionnaire used to measure severity of manic episodes.
4. Brief Psychiatric Rating Scale: used to measure psychiatric symptoms (eg, depression, anxiety, hallucinations).
5. Social and Occupational Functioning Assessment Scale: used to assess functioning on a 0–100 scale (lower scores suggesting greater impairment).
6. Clinical Global Impressions scale: used to measure of clinical improvement.
7. Participants will also be rated on previously established clinical stage and illness trajectory models on the basis of information collected throughout the clinical interview. The clinical staging framework differentiates those in the earliest phases of mental health problems with non-specific clinical presentations (stage 1a; ‘help-seeking’) from those at greater-risk with more specific, subthreshold presentations (stage 1b; ‘attenuated syndromes’) and those who have already reached a threshold for a progressive or recurrent disorder meeting diagnostic criteria (stages 2, 3 or 4). The illness trajectory model is a novel tripartite framework based on three proposed pathophysiological pathways leading to youth-onset mental disorders: (1) neurodevelopmental-psychosis, (2) circadian-bipolar spectrum; and (3) hyperarousal-anxious depression.
8. WHO Alcohol, Smoking and Substance Involvement Screening Test: a reliable, culturally adaptable, valid screener for problematic or risky substance use.

**Self-report assessments**
The self-report questionnaires are tailored to the individual (using skip logic) so the amount of time taken to complete the questionnaire varies, but we estimate the assessment will take 45 min to complete.

1. Demographics and Mental Health History: including details of work and education, physical health (height, weight, waist circumference), history of mental health and family history
2. International Physical Activity Questionnaire-short version: seven-item questionnaire providing internationally comparable data on health-related physical activity.
3. Alcohol Use Disorders Identification Test-Consumption: includes three short questions that estimate alcohol consumption in a standard,
| **Table 1** Primary, secondary, and tertiary outcome measures. |
|-------------------------------------------------------------|
| **Primary outcome measures** (Correlation between change in sleep-wake and circadian parameters and change in depressive symptoms from baseline to week eight) | **Secondary outcome measures** (Correlation between change in sleep-wake and circadian parameters and change in functioning from baseline to week eight) | **Tertiary outcome measures** (Correlation between change in sleep-wake and circadian parameters and other multidimensional outcome measures) |
| Primary depressive symptom measures: | Functioning measures: | Symptom measures: |
| ► QIDS-CR total score (minus sleep items) | ► Social and Occupational Functioning Assessment Scale (SOFAS) rating | ► Young Mania Rating Scale total score |
| ► QIDS-SR total score (minus sleep items) | ► The Work and Social Adjustment Scale (WSAS) total score | ► Brief Psychiatric Rating Scale total score and subscale scores |
| ► The Montgomery-Åsberg Depression Rating Scale total score (minus sleep items) | ► Adapted Schuster Social Support Scale total score | ► Overall Anxiety Severity Impairment Scale total score |
| **Sleep-wake and circadian variables:** | ► Not in Education, Employment, or Training (NEET) status | ► Altman Self-Rating Mania scale total score |
| Actigraphy parameters (in the 2-week period prior to baseline and prior to week eight): | ► Number of days ‘out of role’ (unable to perform usual activities) in the past 30 days | ► Prodromal Questionnaire (brief version) total score |
| ► Sleep-onset time | | ► DSM-5 Primary Care Post-Traumatic Stress Disorder screening total score |
| ► Sleep offset (wake) time | | ► Adapted Eating Disorder Examination total score |
| ► Total sleep time (duration) | | ► Clinical Global Impressions scales severity and improvement scores |
| ► Wake after sleep onset (estimation of number of minutes awake during the sleep period) | | **Self-harm and suicidal thoughts and behaviours:** |
| ► Sleep efficiency (% of sleep period estimated as sleep) | | ► Suicidal risk (score from Suicidal Ideation Attributes Scale and Columbia-Suicide Severity Rating Scale items) |
| ► Inter-daily stability | | ► Adapted Brief Non-Suicidal Self-Injury Assessment Tool total score |
| ► Intradaily variability | | **Physical health:** |
| **In-lab circadian measures:** | | ► Body mass index calculated from height and weight |
| Dim Light Melatonin Onset (DLMO) timing | | ► Waist circumference |
| Phase angle (time lapse) between DLMO and habitual sleep | | ► International Physical Activity Questionnaire total score |
| Core body temperature nadir | | ► Metabolic blood markers including triglycerides, cholesterol (total, low-density lipoprotein, high-density lipoprotein), and Homeostasis Model of Insulin Resistance calculated from fasting glucose and insulin measures |
| Evening cortisol area under the curve | | ► Inflammatory blood markers including interleukin-1β, interleukin-6, tissue necrosis factor, C reactive protein |
| **Self-report measures:** | | **Alcohol and substance Use:** |
| Non-restorative sleep score (based on the Pittsburgh Sleep Quality Index (PSQI), and Munich Chrono Type Questionnaire) | | ► WHO Alcohol, Smoking, and Substance Involvement Screening Test (WHO ASSIST) score for tobacco and cannabis |
| PSQI total score | | ► Alcohol Use Disorders Identification Test-Consumption total score |
| Epworth Sleepiness Score total score | | ► WHO ASSIST alcohol-related impairment |
| Insomnia Severity Index total score | | ► Age of onset of alcohol use |
| Morningness -Eveningness Questionnaire total score* | | **Comparison of primary endpoints between:** |
| Seasonal Pattern Assessment Questionnaire total score* | | ► Clinical stages |
| **Comparison of primary endpoints between:** | | ► Illness trajectories |
| ► Clinical stages | | ► Genetic variants with potential relevance to mood disorders and/or circadian rhythms (eg, CLOCK, BMAL1). |

*Baseline scores will be used rather than change scores as these are trait measures.
QIDS-CR, Clinical-rated Quick Inventory of Depressive Symptomatology; QIDS-SR, Quick Inventory of Depressive Symptomatology-self-report.
meaningful, non-judgemental manner. Additional questions assessing age of onset of alcohol consumption will also be used.

4. Suicidal Ideation Attributes Scale (SIDAS): five-item self-report questionnaire assessing the frequency, controllability, closeness to attempt, distress and interference with daily activities on a 10-point Likert scale over the past month.

5. Columbia-Suicide Severity Rating Scale: The scale comprises three sections: suicidal ideation, intensity of ideation and suicidal behaviour. A self-rating adaptation will be used in combination with the SIDAS.

6. Brief Non-Suicidal Self-Injury Assessment Tool: designed to assess primary (such as form, frequency, and function) and secondary (including but not limited to NSSI habituation; contexts in which NSSI is practiced; and NSSI perceived life interference, treatment, and impacts) NSSI characteristics.

7. Quick Inventory of Depressive Symptomatology – self-report (QIDS-SR): a self-rating version includes 16 questions with equivalent weightings (0–3) for each symptom item that assesses the nine criterion symptom domains designated by the DSM-IV to diagnose an MDE.

8. Overall Anxiety Severity Impairment Scale: five-item self-report measure used to assess severity and impairment associated with any anxiety disorder or multiple anxiety disorders.

9. Altman Self-Rating Mania Scale: five-item self-rating scale designed to assess the presence and/or severity of manic symptoms.

10. Primary Care Post-Traumatic Stress Disorder Screen for DSM-5: five-item screen designed for use in primary care settings to identify respondents with probable PTSD.

11. Prodromal Questionnaire: self-report screen for use in secondary mental healthcare services to select subjects for psychosis risk.

12. Eating Disorder Examination: comprises a range of health-related and demographic questions, including present height and weight, and a detailed and comprehensive assessment of symptoms, particularly binge eating. In this study, three eating disorder behaviours are assessed: binge eating, purging and strict dieting or fasting.

13. Sleep questions: seven questions regarding time falling asleep, waking up during weekdays and weekends, hours of sleep, feelings when waking up. Sleep timing items are based on the Pittsburgh Sleep Quality Index (PSQI) and Munich Chrono Type Questionnaire, while sleep quality items are based on expert consensus in the literature.

14. Work and Social Adjustment Scale: five-item scale of functional impairment attributable to an identified problem.

15. Schuster Social Support Scale: 15-item measure of social support used to examine an individual’s social relationships with others (relatives, friends, spouse) and the associated impact on their emotional functioning.

16. Additional sleep questionnaires: participants will complete the BMC sleep-wake self-report questionnaire battery including questions regarding ethnicity, caffeine consumption, menstrual cycle, visual impairments, and non-restorative sleep, as well as the PPSQI, Epworth Sleepiness Scale, Insomnia Severity Index, Horne-Ostberg Morningness-Eveningness Questionnaire and the Seasonal Patterns Assessment Questionnaire.

**Sleep wake assessments**

24-hour sleep-wake and circadian rest-activity parameters will be measured by actigraphy recordings. Actigraphy is a non-invasive tool to objectively measure activity profiles and used to estimate sleep and circadian patterns based on validated algorithms. Participants will be asked to complete a sleep diary and to wear an actigraph (GENEActiv device; Activinsights, Kimbolton, UK) on the non-dominant wrist for at least 10 days prior to commencing the study, and continuously for the 8-week treatment phase. The device is a comfortable and easy to use, battery operated wrist-worn device (similar in appearance to a Fitbit), designed to record and provide data on movement, light, temperature and sleep patterns. The device will provide objective monitoring of participants’ 24-hour circadian rhythm, including their sleep onset and duration, rise time, night-time sleep interruptions, and activity patterns (see table 1). The device allows for the outputting of real-time raw measurement data for up to a month without charging. Instructions will be provided to participants on how to use the device on their recruitment into the study. Two-week actigraphy recordings will also be completed at the 12-week and 16-week follow-up assessments. GENEActiv devices have been validated against several types of accelerometry-based activity monitors as well as for sleep-wake scoring. For decades, actigraphy monitors like the GENEActiv devices have been used extensively in research to measure sleep and activity patterns in diverse clinical settings including sleep disorders, medical illnesses (e.g., neurodegenerative diseases) and various major mental disorders.

**In-lab circadian assessment**

Circadian rhythms will be measured in an evening/overnight recording period, including 24-hour rhythms of salivary melatonin, salivary cortisol and core body temperature (table 1). Circadian assessments will be performed in accordance with established dim light melatonin onset protocols.

**Metabolic and inflammatory markers**

The following markers will be collected at baseline and 8 weeks follow-up visits: (1) triglycerides, (2) cholesterol (including total, high-density lipoprotein and low-density lipoprotein), (3) fasting glucose, (4) fasting insulin, (5) interleukin (IL)-1β,

Carpenter JS, et al. BMJ Open 2022;12:e056298. doi:10.1136/bmjopen-2021-056298
Carpenter JS, et al. BMJ Open 2022;12:e056298. doi:10.1136/bmjopen-2021-056298

(6) IL-6, (7) tissue necrosis factor-α and (8) C-reactive protein. Height, weight and waist circumference will be recorded. Insulin resistance will be estimated based on paired fasting plasma glucose and insulin levels by the updated homeostatic model assessment (HOMA2-IR) using iHOMA2 software V.8.8.

Genetics

Additional blood (30mL) will be collected at baseline for assessment of genetic markers as per procedures from the University of Queensland Human Studies Unit.

The schedule of trial assessments is summarised in table 2 and the participant timeline is presented in figure 1.

Safety and side effects monitoring

Studies have shown that brexpiprazole is generally well tolerated, with no unexpected or severe side effects. Safety and tolerability of the investigational product (IP) will be closely monitored throughout the trial. For the duration of the 8-week treatment period, weekly phone calls will be conducted to monitor safety and elicit information regarding side effects and potential adverse events. Any changes in concomitant medications will also be investigated and recorded. In addition, participants will be provided with a medication diary and asked to complete during the study to monitor tolerability and adherence. According to the IP information, participants will be advised to not drive a car, operate machinery or do other dangerous activities until they know how the IP affects them, as it may induce drowsiness in some subjects.

Further formal assessment of side effects and potential adverse events following the end of the treatment phase will be conducted at the two follow-up visits (visits 4 and 5). At the baseline visit, participants will be informed that any serious negative side effects should be reported to the study doctor immediately and will be provided with the relevant contact details to do so. All adverse events will be assessed for causality and symptom severity according to the study protocol and followed up by the study doctor if required. In the occurrence of a serious adverse event, appropriate diagnostic and therapeutic measures will be taken and the participant will be kept under observation for as long as is medically indicated. The principal investigator will then determine if the seriousness of the event warrants the removal of the participant from the study or abandonment of the study. For serious side effects or medical problems, the patient may be taken immediately to Royal Prince Alfred Hospital for treatment. The principal investigator will ensure that follow-up of the participant is appropriate to the nature of any event, and that it continues until resolution.

Throughout the trial the study doctor will monitor participants for pregnancy. It is not currently included in the protocol, but the trial Standard Operating Procedures manual explains that the study doctor will give relevant contraception advice to participants based on the current IP information.

Table 2 Schedule of assessments

| Study week | Visit 1 (baseline) | Visit 2 (week 4) | Visit 3 (week 8) | Visit 4 (follow-up 1) | Visit 5 (follow-up 2) |
|------------|-------------------|------------------|------------------|----------------------|---------------------|
| Enrolment visit | 0 | 4 | 8 | 12 | 16 |
| Informed consent | ✓ | | | | |
| Inclusion/exclusion criteria | ✓ | ✓ | | | |
| Diagnostic Assessment (SCID) | ✓ | | | | |
| Mental Risk Assessment (CAARMS) | ✓ | ✓ | ✓ | ✓ | ✓ |
| Demographics and mental illness history | ✓ | | | | |
| Clinical Assessment (QIDS-CR, MADRS, YMRS, BPRS, SOFAS) | ✓ | ✓ | ✓ | ✓ | ✓ |
| Self-report assessment | ✓ | ✓ | ✓ | ✓ | ✓ |
| Sleep-wake assessment (actigraphy monitoring) | ✓ | ✓ | ✓ | ✓ | ✓ |
| In-lab circadian assessment | ✓ | | | | |
| Blood sample collection (Metabolic and inflammatory markers) | ✓ | | | | |
| Safety, side effects and adherence assessment | ✓ | ✓ | ✓ | ✓ | ✓ |
| IP dispensing | ✓ | ✓ | ✓ | ✓ | ✓ |
| IP return | ✓ | | | | |

*If clinically indicated, at the discretion of the treating clinician.

BPRS, Brief Psychiatric Rating Scale; CAARMS, Comprehensive Assessment of At-Risk Mental States; IP, investigational product; MADRS, Montgomery-Åsberg Depression Rating Scale; QIDS-CR, Clinician-rated Quick Inventory of Depressive Symptomatology; SCID, Structured Clinical Interview for DSM; SOFAS, Social and Occupational Functioning Assessment Scale; YMRS, Young Mania Rating Scale.
Sample size calculation

Sample size was determined based on a study of circadian changes in response to agomelatine where a coefficient of 0.54 was found for the correlation between change in DLMO and change in depressive symptoms. We conservatively estimated that the coefficient for brexpiprazole...
would be smaller (~0.35; ie, medium effect size), as effects on the circadian system may be less direct. Assuming $\alpha=0.05$ and 80% power for a one-tailed correlation analysis, a sample size of $n=49$ is required to detect this effect.

**Data analysis plan**

Correlations will be performed between change scores (ie, visit 2 score minus visit 1 score) for sleep and circadian measures, and change scores for depressive symptoms. The intention-to-treat principle will be used for missing data (last observations carried forward). Before analysis, plots with outlier and normality statistics will be generated for all variables to identify outliers and issues with variable distribution. Extreme outliers ($\pm 3$ z-scores) will be checked against source data and testing notes to verify whether they are the result of an error in data entry or a specific issue during testing (eg, equipment failure), with errors rectified. If not the result of data entry error, outliers will be curtailed. Pearson’s or Spearman’s correlations will be selected to perform analyses based on normative or non-normative data distribution (significance level $\alpha=0.05$). Correlations will also be examined between other change scores to assess secondary and tertiary endpoints. Further tertiary endpoints will be assessed by partial correlations comparing categorical variables.

**Patient and public involvement**

Clinical professionals working with young people with mental health problems were invited to comment on the study design and procedures. Findings will be disseminated to scientific, clinical and wider communities.

**ETHICS AND DISSEMINATION**

This trial has been approved by the Human Research Ethics Committee of the Sydney Local Health District (X19-0417 and 2019/ETH12986, Protocol Version 1–3, dated 25 February 2021). The study will be conducted in compliance with all stipulations of the protocol, the conditions of ethics committee approval, the NHMRC National Statement on Ethical Conduct in Human Research and the Good Clinical Practice guidelines. The results of this study will be disseminated as widely as possible into the scientific and broader community. This will include publication in peer-reviewed journals, scholarly book chapters, presentation at conferences and publication in conference proceedings. Publications arising from this project will be deposited into an open access institutional repository, where possible. Results will also be disseminated into the wider community in a format appropriate for a lay audience, through links including the BMC website and social media, as well as newsletters.

**Acknowledgements**

This work was supported in-part by philanthropic funding, for which donor(s) are families affected by mental illness who wish to remain anonymous.

**Contributors**

JSC and IBH conceived the study, led the proposal and protocol development. JSC wrote the trial protocol. AG drafted the first version of the manuscript. NZ drafted the final version of the manuscript with input from other authors. JSC, AG, AN, NZ, JYCS, CW, CR, JC, CM, FML, DK and EMS were all involved with modifications to the design of the study and with drafting of this paper. All authors have read and approved the final manuscript.

**Funding**

JSC is supported by a Breakthrough Mental Health Research Foundation Fellowship and an NHMRC Emerging Leadership Fellowship (GN12008197).

**Competing interests**

IBH is the Co-Director, Health and Policy at the Brain and Mind Centre (BMC) University of Sydney, Australia. The BMC operates an early-intervention youth services at Campbelltown under contract to headspace. Professor Hickie has previously led community-based and pharmaceutical industry-supported (Wyeth, Eli Lilly, Servier, Pfizer, AstraZeneca) projects focused on the identification and better management of anxiety and depression. He is the Chief Scientific Advisor to, and a 3.2% equity shareholder in, InnoWELL Pty Ltd. InnoWELL was formed by the University of Sydney (45% equity) and PwC (Australia: 45% equity) to deliver the $30M Australian Government-funded Project Synergy (2017–20) and to lead transformation of mental health services internationally through the use of innovative technologies. EMS is the Medical Director, Young Adult Mental Health Unit, St Vincent’s Hospital Darlinghurst, Discipline Leader of Adult Mental Health, School of Medicine, University of Notre Dame, Research Affiliate, The University of Sydney and Consultant Psychiatrist. She has received honoraria for educational seminars related to the clinical management of depressive disorders supported by Servier and Eli-Lilly pharmaceuticals. She has participated in a national advisory board for the antidepressant compound Pristiq, manufactured by Pfizer. She was the National Coordinator of an antidepressant trial sponsored by Servier.

**Patient and public involvement**

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication**

Not applicable.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iDs**

Joaone S Carpenter http://orcid.org/0000-0002-9766-6700
Natalia Zmierszewska http://orcid.org/0000-0001-7649-4711
Jacob J Crouse http://orcid.org/0000-0002-3805-2936
Alissa Nichles http://orcid.org/0000-0001-6404-7199
Chloe Wilson http://orcid.org/0000-0001-6539-423X
Catharin Rohleder http://orcid.org/0000-0002-3505-1846
Catherine McHugh http://orcid.org/0000-0002-4891-4966

**REFERENCES**

1. Kessler RC, Aguilar-Gaxiola S, Alonso J, et al. The global burden of mental disorders: an update from the who world mental health (WMH) surveys. *Epidemiol Psychiatr Soc* 2009;18:23–33.
2. Gore FM, Bloem PJN, Patton GC, et al. Global burden of disease in young people aged 10–24 years: a systematic analysis. *Lancet* 2011;377:2093–102.
3. Kennard BD, Silva SG, Tonev S, et al. Remission and recovery in the treatment for adolescents with depression study (TADS): acute and long-term outcomes. *J Am Acad Child Adolesc Psychiatry* 2009;48:186–95.
4. March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for adolescents with depression study (TADS) randomized controlled trial. *JAMA* 2004;292:807–20.
5. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. *Am J Psychiatry* 2006;163:1905–17.
6. Murphy SE, Capitão LP, Giles SLC, et al. The knowns and unknowns of SSRI treatment in young people with depression and anxiety: efficacy, predictors, and mechanisms of action. *Lancet Psychiatry* 2021;8:234–35.
7. Cuijpers P, Karyotaki E, Eckshtain D, et al. Psychotherapy for depression across different age groups: a systematic review and meta-analysis. *JAMA Psychiatry* 2020;77:694–702.
8. Wolpert M, Datzell K, Ullman R, et al. Strategies not accompanied by a mental health professional to address anxiety and depression
in children and young people: a scoping review of range and a systematic review of effectiveness. *Lancet Psychiatry* 2019;6:46–60.

9 Eckstein D, Kuppens S, Ugoato A, et al. Meta-Analysis: 13-year follow-up of psychotherapy effects on youth depression. *J Am Acad Child Adolesc Psychiatry* 2020;59:45–83.

10 Bear HA, Edbrooke-Childs J, Norton S, et al. Systematic review and meta-analysis: outcomes of routine specialist mental health care for young people with depression and/or anxiety. *J Am Acad Child Adolesc Psychiatry* 2020;59:810–41.

11 Zhou X, Ravindran AV, Qin B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. *J Clin Psychiatry* 2015;76:e487–98.

12 Formaro M, Fusco A, Anastasia A, et al. Brexiprazole for treatment-resistant major depressive disorder. *Expert Opin Pharmacother* 2019;20:1925–33.

13 Benca RM, Obermeyer WH, Thisted RA, et al. Insomnia and sleep duration in a large cohort of patients with major depressive disorder and anxiety disorders. *J Clin Psychiatry* 2010;71:239–46.

14 Liu X, Buyse DJ, Gentzler AL, et al. Insomnia and hypersomnia associated with depressive phenomenology and comorbidity in childhood depression. *Sleep* 2007;30:83–90.

15 Geoffroy PA, Hoertel N, Etain B, et al. Insomnia and hypersomnia in major depressive episode: prevalence, sociodemographic characteristics, and psychiatric comorbidity in a population-based study. *J Affect Disord* 2018;226:132–41.

16 Merikangas KR, Swendsen J, Hickie IB, et al. Real-Time mobile monitoring of the dynamic associations among motor activity, energy, mood, and sleep in adults with bipolar disorder. *JAMA Psychiatry* 2019;76:190–8.

17 Difrancesco S, Lamers F, Riese H, et al. Sleep, circadian rhythm, and physical activity patterns in depressive and anxiety disorders: a 2-week ambulatory assessment study. *Depress Anxiety* 2019;36:975–86.

18 Germain A, Kuper DJ. Circadian rhythm disturbances in *Hum Psychopharmacol* 2008;23:571–85.

19 Lamuey L, Mongeau R, Hamon M. Biological rhythms and melatonin in mood disorders and their treatments. *Pharmacol Ther* 2013;138:176–84.

20 Krystal AD, Mittoux A, Lindsten A, et al. Chronobiologic parameter changes in patients with major depressive disorder and sleep disturbance treated with adjunctive brexiprazole: an open-label, flexible-dose, exploratory substudy. *J Affect Disord* 2021;278:288–95.

21 Carpenter JS, Crouse JJ, Scott EM, et al. Circadian depression: a mood disorder phenotype. *Neurosci Biobehav Rev* 2021;126:79–101.

22 Ko CH, Takahashi JS. Molecular components of the mammalian circadian clock. *Hum Mol Genet* 2006;15 Spec No 2:R221–7.

23 Logan RW, Moore CA. Rhythms of life: circadian disruption and brain disorders across the lifespan. *Nat Rev Neurosci* 2019;20:49–65.

24 Carpenter JS, Robillard R, Hicks IB. Variations in the sleep-wake cycle from childhood to adulthood: chronobiological perspectives. *ChronoPhysiol and Therapy* 2015;5:37–49.

25 Robillard R, Naismith SL, Rogers NL, et al. Delayed sleep phase in young people with unipolar or bipolar affective disorders. *J Affect Disord* 2013;145:260–3.

26 Robillard R, Carpenter JS, Rogers NL, et al. Circadian rhythms and psychiatric profiles in young adults with unipolar depressive disorders. *Transl Psychiatry* 2018;8:213.

27 Crowley SJ, Acero C, Caruskad MA. Sleep, circadian rhythms, and delayed phase in adolescence. *Sleep Med* 2007;8:602–12.

28 Roenneberg T, Kuchner T, Pramstaller PP, et al. A marker for the end of adolescence. *Curr Biol* 2004;14:R1038–9.

29 Robillard R, Carpenter JS, Feilds K-L, et al. Parallel changes in mood and melatonin rhythm following an adjunctive multimodal chronobiological intervention with agonametine in people with depression: a proof of concept open label study. *Front Psychiatry* 2019;9:624.

30 Benedetti F, Dallasega S, Fulgosi MC, et al. Phase advance is an actimetric correlate of antidepressant response to sleep deprivation and light therapy in bipolar depression. *Chronobiol Int* 2007;24:291–322.

31 Hobart M, Skuban A, Zhang P, et al. A randomized, placebo-controlled study of the efficacy and safety of fixed-dose Brexiprazole 2 mg/d as adjunctive treatment of adults with major depressive disorder. *J Clin Psychiatry* 2018;79:17m12058.

32 Bauer M, Hefting N, Lindsten A, et al. A randomised, placebo-controlled 24-week study evaluating adjunctive brexiprazole in patients with major depressive disorder. *Acta Neuropsychiatr* 2019;31:1–9.

33 Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexiprazole 1 and 3 Mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. *J Clin Psychiatry* 2015;76:1232–40.

34 Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexiprazole 2 Mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. *J Clin Psychiatry* 2015;76:1224–31.

35 Yoon S, Jeon SW, Ko Y-H, et al. Adjunctive Brexiprazole as a novel effective strategy for treating major depressive disorder: a systematic review and meta-analysis. *J Clin Psychopharmacol* 2017;37:46–53.

36 Citrome L, Stensel TB, Maeda K. The preclinical profile of brexiprazole: what is its clinical relevance for the treatment of psychiatric disorders? *Expert Rev Neurother* 2015;15:1219–29.

37 Beyer JL, Weisler RH. Adjunctive brexiprazole for the treatment of major depressive disorder. *Expert Opin Pharmacother* 2016;17:2331–9.

38 Krystal AD, Mittoux A, Meisels P. Effects of adjunctive Brexiprazole on sleep disturbances in patients with major depressive disorder: an open-label, flexible-Dose, exploratory study. *Prim Care Companion CNS Disord* 2016;18:15m01914.

39 Pillar V, Kalmbach DA, Ciesla JA. A meta-analysis of electroencephalographic sleep in depression: evidence for genetic biomarkers. *Biol Psychiatry* 2011;70:912–9.

40 Palagini L, Baglioni C, Ciapparelli A, et al. Rem sleep dysregulation in depression: state of the art. *Sleep Med Rev* 2013;17:377–90.

41 Wang Y-Q, Li R, Zhang M-Q, et al. The neurobiological mechanisms and treatments of REM sleep disturbances in depression. *Curr Neuropsychopharmacol* 2015;13:943–52.

42 Zhang Y, Ren R, Yang L, et al. Polysomnographically measured sleep changes in idiopathic REM sleep behavior disorder: a systematic review and meta-analysis. *Sleep Med Rev* 2020;54:101362.

43 Hickie IB, Scott EM, Cross SP, et al. Right care, first time: a highly personalised and measurement-based care model to manage youth mental health. *Med J Aust* 2019;211 Suppl 9:S3–46.

44 American Psychiatric Association, Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Pub, 2013.

45 Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. *Biol Psychiatry* 2003;54:573–83.

46 Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. *Aust N Z J Psychiatry* 2005;39:964–71.

47 WHO ASSIST Working Group. The alcohol, smoking and substance involvement screening test (assist): development, reliability and feasibility. *Addiction* 2002;97:1183–94.

48 Humeniuk R, Ali R, Babor TF, et al. Validation of the alcohol, smoking and substance involvement screening test (assist). *Addiction* 2008;103:1039–47.

49 Fava M, Mandr F, Davidson CK, et al. Adjunctive Brexiprazole in patients with major depressive disorder and irritability: an exploratory study. *J Clin Psychiatry* 2016;77:1695–701.

50 Lingjaerde O, Aftfors UG, Bech P, et al. The UKU side effect rating: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. *Acta Psychiatric Scand* 1987;76:1–100.

51 Guy WA. Abnormal Involuntary Movement Scale (AIMS). In: *ECDEU assessment manual for psychopharmacology*. Washington, DC: U.S. Department of Health Education and Welfare, 1976: 534–7.

52 Simpson GM, B, M, B, GH, et al. A rating scale for extrapyramidal side effects. *Acta Psychiatric Scand* 1970;45:11–19.

53 Hickie IB, Scott EM, Hermens DF, et al. Applying clinical staging to young people who present for mental health care. *Early Interv Psychiatry* 2013;7:31–43.

54 McGorry PD, Hickie IB, Yung AR, et al. Clinical staging of psychiatric disorders: a heuristic framework for choosing, safer and more effective interventions. *Aust N Z Psychiatry* 2006;40:616–22.
Carpenter JS, et al. BMJ Open 2022;12:e056298. doi:10.1136/bmjopen-2021-056298

57 Scott J, Leboyer M, Hickie I, et al. Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value. Br J Psychiatry 2013;202:243–5.

58 Hickie IB, Scott J, McGorry PD. Clinical staging for mental disorders: a new development in diagnostic practice in mental health. Med J Aust 2013;198:461–2.

59 Hickie IB, Hermens DF, Naismith SL, et al. Evaluating differential developmental trajectories to adolescent-onset mood and psychotic disorders. BMC Psychiatry 2013;13:303.

60 Crouse JJ, Carpenter JS, Orfino F, et al. Transdiagnostic neurocognitive subgroups and functional course in young people with emerging mental disorders: a cohort study. BJPsych Open 2020;6:e31.

61 Carpenter JS, Orfino F, Cross S, et al. Cohort profile: the Brain and Mind Centre Optymise cohort: tracking multidimensional outcomes in young people presenting for mental healthcare. BMJ Open 2020;10:e000985.

62 Scott EM et al. Early intervention, prevention, and prediction in mood disorders: Tracking multidimensional outcomes in young people presenting for mental health care. In: Personalized psychiatry. Elsevier, 2020: 39–62.

63 Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–9.

64 Young RC, Lerman KV, Orfino F, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429–35.

65 Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799–812.

66 Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM IV: a review of measures of social functioning. Am J Psychiatry 1992;149:1148–66.

67 Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry 2007;4:7-28.

68 Crouse JJ, Carpenter JS, Song YJC, et al. A review of measures of social functioning. J Occup Health 2011;53:126–39.

69 Booth M. Assessment of physical activity: an international cross-cutting model of diagnosis with heuristic and practical value. Clinical staging in psychiatry: a Br J Psychiatry 2014;197:255–7.

70 Prins A, Bovin MJ, Smolenski DJ, et al. The primary care PTSD screen for DSM-5 (PC-PTSD-5): development and evaluation within a veteran primary care sample. J Gen Intern Med 2016;31:1206–11.

71 Ising HK, Veling W, Lowey RL, et al. The validity of the 16-item version of the prodromal questionnaire (PQ-16) to screen for ultra high risk of developing psychosis in the general help-seeking population. Schizophr Bull 2012;38:1288–96.

80 Hay PJ, Mond J, Buttnar P, et al. Eating disorder behaviors are increasing: findings from two sequential community surveys in South Australia. PLoS One 2008;3:e1541.

81 Mitchison D, Hay P, Siewa-Younan S, et al. The changing demographic profile of eating disorder behaviors in the community. BMC Public Health 2014;14:943.

82 Mundt JC, Marks IM, Shear MK, et al. The work and social adjustment scale: a simple measure of impairment in functioning. Br J Psychiatry 2002;180:461–4.

83 Schuster TL, Kessler LM, & Bobo J. Supportive interactions, negative interactions, and depressed mood. Am J Community Psychol 1990;18:423–38.

84 Buyssse DJ, Reynolds CF, Monk TH, et al. The Pittsburgh sleep quality index: a new instrument for psychiatic practice and research. Psychiatry Res 1998;79:67–79.

85 Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness scale. Sleep 1991;14:540–5.

86 Bastien CH, Vallières A, Morin CM. Validation of the insomnia severity index as an outcome measure for insomnia research. Sleep Med 2001;2:97–107.

87 Horne JA, Ostberg O. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol 1976;4:97–110.

88 Rosenthal NE et al. Sleep estimates using microelectroencephalographic systems (MEMPS). Sleep 2013;36:781–9.

89 van Hees VT, Scharf RJ, et al. Establishing and evaluating cutoff points for the GENEActiv accelerometer in adults. PLoS One 2014;9:e82663.

90 Hildebrand M, VAN Hees VT, Hansen BH, et al. Age group comparability of raw accelerometer output from wrist- and hip-worn monitors. Med Sci Sports Exerc 2014;46:1816–24.

91 Esliger DW, Rowlands AV, Hurst TL, et al. Validation of the GENEActiv Accelerometer. Med Sci Sports Exerc 2011;43:1085–93.

92 van Hees VT, Gorgziello A, Dean LE, et al. Separating movement and gravity components in an acceleration signal and implications for the assessment of human daily physical activity. PLoS One 2015;10:e0142533.

93 te Lindert BHW, Van Someren EJW. Sleep estimates using microelectroencephalographic systems (MEMPS). Sleep 2013;36:781–9.

94 van Hees VT, Sabia S, Anderson KN, et al. A novel, open access method index to assess sleep duration using a Wrist-Worn Accelerometer. PLoS One 2015;10:e0142533.

95 Stone JE, McGlashan EM, Facer-Childs ER, et al. Accuracy of the GENEActiv device for measuring light exposure in sleep and circadian research. Clocks Sleep 2020;2:143–52.

96 Hill NR, Levy JC, Matthews DR. Use and abuse of HOMA-β to enable clinical trial outcome modeling through the interactive adjustment of physiology and treatment effects: iHOMA2. Diabetologia 2014;57:1997–2004.

97 Lewy AJ, Sack RL. The dim light melatonin onset as a marker for circadian phase. Chronobiol Int 1998;15:93–102.

98 de Almeida EA, Di Mascio P, Harumi T, et al. Measurement of melatonin in body fluids: Standards, protocols and procedures. Chronobiol Int 2011;28:789–91.

99 Voutilainen A, Kinnunen J, Dawson D. Salivary melatonin as a circadian phase marker: validation and comparison to plasma melatonin. J Biol Rhythms 1990;15:47–46.

100 Pandi-Perumal SR, Smit M, Spence W, et al. Dim light melatonin onset (DLO) as a tool for the analysis of circadian phase in human sleep and chronobiological disorders. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1–11.

101 Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487–95.

102 Hill NR, Levy JC, Matthews DR. Expansion of the homeostasis model assessment of β-cell function and insulin resistance to enable clinical trial outcome modeling through the interactive adjustment of physiology and treatment effects: iHOMA2. Diabetes Care 2013;36:2324–30.

103 Lepola U, Hefting N, Zhang D, et al. Adjunctive brexpiprazole for elderly patients with major depressive disorder: an open-label, long-term safety and tolerability study. Int J Geriatr Psychiatry 2018;33:1403–10.

104 Hakala M, Gislum M, Skuban A, et al. O7.5. long-term safety and tolerability of BREXIPRRAZOLE in patients with schizophrenia. Schizophr Bull 2018;44:S94–5.